Holen Sie sich die Stockscreener-App
18.91
2.77%
0.51
Handel nachbörslich:
18.87
-0.04
-0.21%
Schlusskurs vom Vortag:
$18.40
Offen:
$18.59
24-Stunden-Volumen:
707.75K
Relative Volume:
0.92
Marktkapitalisierung:
$1.38B
Einnahmen:
$9.98M
Nettoeinkommen (Verlust:
$-154.08M
KGV:
-7.3295
EPS:
-2.58
Netto-Cashflow:
$-159.66M
1W Leistung:
-9.22%
1M Leistung:
+20.22%
6M Leistung:
-28.56%
1J Leistung:
-55.20%
1-Tages-Spanne:
$17.85
$19.24
1-Wochen-Bereich:
$17.85
$21.23
52-Wochen-Spanne:
$14.40
$47.00
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Firmenname
Celldex Therapeutics Inc
Sektor
Branche
Telefon
908-200-7500
Adresse
53 FRONTAGE ROAD, HAMPTON
Vergleichen Sie CLDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
18.91 | 1.38B | 9.98M | -154.08M | -159.66M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.82 | 130.98B | 11.10B | -988.90M | -978.00M | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 64.65B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
622.93 | 39.39B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.55 | 34.32B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
232.25 | 28.03B | 3.81B | -644.79M | -669.77M | -6.24 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-28 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-03-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-02-13 | Eingeleitet | UBS | Buy |
| 2024-10-07 | Eingeleitet | Citigroup | Buy |
| 2024-09-30 | Eingeleitet | Goldman | Neutral |
| 2024-09-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | Eingeleitet | Stifel | Buy |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-20 | Eingeleitet | TD Cowen | Outperform |
| 2023-11-10 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | Eingeleitet | Wells Fargo | Underweight |
| 2021-09-17 | Eingeleitet | Jefferies | Buy |
| 2021-09-10 | Eingeleitet | SVB Leerink | Outperform |
| 2021-07-22 | Eingeleitet | Guggenheim | Buy |
| 2020-02-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-08-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-07 | Eingeleitet | Aegis Capital | Buy |
| 2016-03-08 | Herabstufung | Jefferies | Buy → Hold |
| 2016-03-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2016-03-07 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2016-03-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-08-11 | Bestätigt | Brean Capital | Buy |
| 2015-08-11 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-11 | Bestätigt | ROTH Capital | Buy |
| 2015-06-02 | Bestätigt | WBB Securities | Strong Buy |
| 2014-11-17 | Bestätigt | ROTH Capital | Buy |
| 2014-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2013-07-08 | Bestätigt | Cantor Fitzgerald | Buy |
| 2013-03-08 | Bestätigt | Cantor Fitzgerald | Buy |
| 2013-02-26 | Bestätigt | Oppenheimer | Outperform |
| 2013-01-10 | Bestätigt | Cantor Fitzgerald | Buy |
| 2012-10-02 | Bestätigt | Oppenheimer | Outperform |
| 2012-09-14 | Bestätigt | Cantor Fitzgerald | Buy |
Alle ansehen
Celldex Therapeutics Inc Aktie (CLDX) Neueste Nachrichten
Stock Market Recap: Celldex Therapeutics Inc (CLDX) Concludes at 18.40, a -9.31 Surge/Decline - DWinneX
Cantor Fitzgerald maintains Celldex stock Overweight with $67 target By Investing.com - Investing.com Canada
Celldex Therapeutics (CLDX) Receives Reiterated 'Buy' Rating fro - GuruFocus
Celldex Therapeutics (CLDX) Receives Reiterated 'Buy' Rating from HC Wainwright | CLDX Stock News - GuruFocus
New Clinical Data Reveals Breakthrough Potential for Celldex's EoE Treatment at Major Medical Conference - Stock Titan
Celldex: Q4 Earnings Snapshot - Barchart.com
Market Insights: Celldex Therapeutics Inc (CLDX)’s Notable Drop of -0.58, Closing at 20.71 - DWinneX
A look into Celldex Therapeutics Inc (CLDX)’s deeper side - Sete News
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Celldex Therapeutics Inc’s results are impressive - uspostnews.com
The Attractiveness of Investing In Celldex Therapeutics Inc (CLDX) is Growing - knoxdaily.com
Celldex Therapeutics (NASDAQ:CLDX) Coverage Initiated by Analysts at Canaccord Genuity Group - Defense World
Analyst Expectations For Celldex Therapeutics's Future - Benzinga
This Kohl's Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday - Benzinga
Canaccord Genuity Initiates Coverage of Celldex Therapeutics (CLDX) with Buy Recommendation - Nasdaq
Canaccord Genuity Initiates Coverage on Celldex Therapeutics With Buy Rating, $64 Price Target - marketscreener.com
Canaccord Initiates Coverage on Celldex (CLDX) with a Positive O - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Celldex Therapeutics Inc [CLDX] Records 200-Day SMA of $28.24 - knoxdaily.com
Regeneron Pharmaceuticals, Inc [REGN] Shares Rise 0.40 % on Wednesday - knoxdaily.com
How to interpret Celldex Therapeutics Inc (CLDX)’s stock chart patterns - uspostnews.com
Chronic Spontaneous Urticaria Market Set for Robust Growth From - openPR.com
Celldex Therapeutics: Strong Pipeline But Uncertainties Remain (NASDAQ:CLDX) - Seeking Alpha
Commit To Purchase Celldex Therapeutics At $15, Earn 20.1% Annualized Using Options - Nasdaq
Urticaria Pipeline: 20+ Innovators Driving the Next Wave of Advanced Treatment Options | DelveInsight - openPR.com
Vanguard Group Inc. Acquires 12,213 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Celldex stock touches 52-week low at $14.57 amid market challenges - Investing.com Australia
Celldex stock touches 52-week low at $14.57 amid market challenges By Investing.com - Investing.com South Africa
KLP Kapitalforvaltning AS Takes $306,000 Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Corebridge Financial Inc. Reduces Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Global Cholera Vaccines Market Detailed In New Research Report - openPR.com
Celldex Therapeutics Enters Oversold Territory (CLDX) - Nasdaq
Teacher Retirement System of Texas Buys 2,819 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Celldex stock touches 52-week low at $18.52 amid market challenges - Investing.com Philippines
Celldex stock touches 52-week low at $18.52 amid market challenges By Investing.com - Investing.com South Africa
When (CLDX) Moves Investors should Listen - news.stocktradersdaily.com
Swiss National Bank Increases Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Global Cholera Vaccines Market Business Outlook ,Growth - openPR.com
Hive Of ActivityCelldex To Report Long-term Results Of Urticaria Drug - RTTNews
Why Celldex Deserves Your Attention? - RTTNews
Charles Schwab Investment Management Inc. Increases Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
7 Analysts Have This To Say About Celldex Therapeutics - Benzinga
Celldex a new overweight at Morgan Stanley on urticaria candidate - Seeking Alpha
This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Morgan Stanley Initiates Coverage of Celldex Therapeutics (CLDX) with Overweight Recommendation - Nasdaq
MS starts coverage on Celldex, bullish view on company's skin disease treatment - TradingView
Morgan Stanley Initiates Celldex Therapeutics at Overweight With $46 Price Target -March 20, 2025 at 07:14 am EDT - MarketScreener
Personalized Cancer Vaccines Market | Growth, Innovations & - openPR
Brokerages Set Celldex Therapeutics, Inc. (NASDAQ:CLDX) PT at $55.38 - The AM Reporter
Strategies for Managing Chronic Spontaneous Urticaria - Medscape
Celldex Therapeutics Inc’s Stock Price Plummeted Recently, But There Might Be Trouble Ahead - stocksregister.com
Finanzdaten der Celldex Therapeutics Inc-Aktie (CLDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.60%
2.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):